STOCK TITAN

Alx Oncology Holdings Inc - ALXO STOCK NEWS

Welcome to our dedicated news page for Alx Oncology Holdings (Ticker: ALXO), a resource for investors and traders seeking the latest updates and insights on Alx Oncology Holdings.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Alx Oncology Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Alx Oncology Holdings's position in the market.

Rhea-AI Summary
ALX Oncology announces positive Phase 2 data for evorpacept in gastric cancer treatment, with a confirmed overall response rate of 52% compared to 22% for the control group. Median duration of response was not reached for evorpacept. Safety profile consistent with previous trials. Results compare favorably to standard of care. Company plans to initiate Phase 3 study in late 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
56.13%
Tags
-
Rhea-AI Summary
ALX Oncology Holdings Inc. to share interim Phase 2 ASPEN-06 clinical trial results of evorpacept for advanced HER2-positive gastric cancer in investor call and webcast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
56.13%
Tags
conferences clinical trial
-
Rhea-AI Summary
ALX Oncology appoints Jason Lettmann as CEO and Dr. Jaume Pons transitions to Chief Scientific Officer. Lettmann brings extensive experience in the biotechnology industry and has been involved with ALX Oncology since its founding. Pons will focus on supporting evorpacept and pipeline extension programs. Lettmann's appointment comes as the company's lead platform asset, evorpacept, advances to later stages of clinical development. Phase 2 data for evorpacept's ASPEN-06 program in HER2-positive gastric cancer is expected in Q4'23.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.37%
Tags
management
Rhea-AI Summary
ALX Oncology Holdings Inc. to participate in two upcoming investor conferences.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.07%
Tags
none
-
Rhea-AI Summary
ALX Oncology Holdings Inc. (ALXO) advances Phase 2/3 ASPEN-06 gastric cancer trial with data update expected in Q423. Terminating ASPEN-02 in MDS and ASPEN-05 in AML. Continuing focus on combinations with anti-cancer antibodies, antibody-drug conjugates, and PD-1/PD-L1 immune checkpoint inhibitors. Financial results for Q2 2023 reported.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.4%
Tags
-
Rhea-AI Summary
ALX Oncology Holdings Inc. reported financial results for Q1 2023, with cash, cash equivalents, and investments of $256.2 million. R&D expenses were $24.8 million, and G&A expenses were $7.4 million. The GAAP net loss was $30.2 million. Recent clinical developments include the initiation of multiple clinical trials for evorpacept in combination with other drugs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.15%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.36%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.45%
Tags
none
Alx Oncology Holdings Inc

Nasdaq:ALXO

ALXO Rankings

ALXO Stock Data

726.70M
22.30M
2.67%
97.6%
6.22%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
South San Francisco

About ALXO

alx oncology (previously alexo therapeutics) is a clinical-stage immuno-oncology company developing therapies that block the cd47 myeloid checkpoint mechanism exploited by cancer cells to evade the immune system. our lead candidate, alx148, is a fusion protein that comprises an engineered high affinity cd47 binding domain of sirpa linked to an inactive fc region of human immunoglobulin. alx148 is currently being investigated in a phase 1 study in combination with checkpoint inhibitors and targeted anti-cancer antibodies (nct03013218). for more information about the company, please visit our website at www.alxoncology.com